The FirstTake Podcast – GSK targets iTeos to advance its TIGIT aspirations

FirstTake on Pharma - Pharma News and Analysis Podcast

English - June 17, 2021 19:00 - 10 minutes - 8.01 MB - ★★★★★ - 2 ratings
Science pharma pharmaceutical intelligence firstword firsttake cardiovascular dermatology diabetes immunology infectious diseases Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: The FirstTake Podcast – FirstWord’s editors discuss the controversial approval of Biogen’s Aduhelm

Next Episode: The FirstTake Podcast – Eli Lilly makes regulatory U turn with Alzheimer’s hopeful

Earlier this week GlaxoSmithKline announced it will pay iTeos Therapeutics $625 million dollars upfront to gain exclusive co-marketing rights for the latter’s anti-TIGIT monoclonal antibody EOS-448, as part of a deal potentially worth over $2 billion.
The drug is currently in Phase I development for advanced solid tumours and this collaboration represents the latest move by GlaxoSmithKline to build out its cancer pipeline.
FirstWord Pharma PLUS executive editor Simon King spoke to Jo Jenkins, chief medical officer at iTeos about the deal, EOS-448 and the competitive anti-TIGIT field where the likes of Roche, Merck & Co. and Bristol Myers Squibb are all active.